Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Isovue-128 — ISOVUE-128
Application NDA018735 (NDA)
Prohance — PROHANCE
Application NDA020131 (NDA)
Isovue-128 — ISOVUE-200
Application NDA020327 (NDA)
Prohance — PROHANCE MULTIPACK
Application NDA021489 (NDA)
Multihance — MULTIHANCE
Application NDA021357 (NDA)
Multihance — MULTIHANCE MULTIPACK
Application NDA021358 (NDA)
Lumason — LUMASON
Application NDA203684 (NDA)
E-Z-Cat Dry — VARIBAR PUDDING
Application NDA208844 (NDA)
E-Z-Cat Dry — E-Z-CAT DRY
Application NDA208036 (NDA)
E-Z-Cat Dry — ENTERO VU 24%
Application NDA208143 (NDA)
Iomervu — IOMERVU
Application NDA216017 (NDA)
Iomervu — IOMERVU
Application NDA216016 (NDA)
E-Z-Cat Dry — E-Z-DISK
Application NDA219840 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)